USA flag logo/image

An Official Website of the United States Government

Polynitroxylated Pegylated Hemoglobin for Traumatic Brian Injury Resuscitation

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R43ES023493
Solicitation Year:
2013
Solicitation Topic Code:
NIEHS
Solicitation Number:
ES13-003
Small Business Information
PRIMORIGEN BIOSCIENCES, INC.
510 CHARMANY DRIVE MADISON, WI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: Polynitroxylated Pegylated Hemoglobin for Traumatic Brian Injury Resuscitation
Agency: HHS
Contract: 1R43ES023493-01
Award Amount: $224,479.00
 

Abstract:

Primorigen Biosciences (R) Abstract Primorigen Biosciences will use SBIR funds to develop a novel commercial assay that measures the toxicity of compounds on human induced pluripotent stem cells (hiPSCs) differentiating into hematopoietic progenitor cells(HPCs) and on HPCs differentiated from hiPSCs. The assay will rely on Primorigen's highly efficient, patent-pending MesoTotal medium for differentiating hiPSCs into HPCs. Phase I studies will optimize HPC differentiation and analysis for high-throughput screening formats, determine toxic impact that compounds have on hiPSCs differentiating into HPCs, and screen for compounds that exhibit toxicity towards hematopoietic progenitor cells derived from hiPS cells. In Phase II, we will enhance commercial applications by a) adapting the system to 384-well HTS formats, b) increasing genetic diversity by including additional hiPSC lines, c) testing a larger library and mixtures indicative of typical environmental exposure, and d) completing secondary screenings to establish dosing efficacy and mechanism of actions. In Phase III, the assay system will be evaluated for potential pharmaceutical development applications. The commercial application is a robust scalable human assay system for screening to assess compound toxicity against hiPS cells differentiating into HPCs. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Current methods for toxicology screening rely on animal models or transformed human cell lines, neither of which can recapitulate fully the developmental processes and mature cell phenotypes of human tissues. Human induced pluripotent stem cell (hiPSC) -derived hematopoietic progenitor cells (HPCs) offer a unique cell source for examining the effects of toxicants upon differentiation processes and upon the mature hematopoietic progenitor cell. Primorigen Biosciences will develop a high throughput hematopoietic progenitor cell screening method that will enable screening of compound libraries for toxic effects.

Principal Investigator:

Bradley H. Garcia
608-628-5189
brad.garcia@primorigen.com

Business Contact:

Chuck Oehler
608-441-8332
chuck.oehler@primorigen.com
Small Business Information at Submission:

PRIMORIGEN BIOSCIENCES, INC.
510 CHARMANY DRIVE MADISON, WI -

EIN/Tax ID: 101096882
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No